CN103153340A - 对肿瘤疾病的治疗 - Google Patents

对肿瘤疾病的治疗 Download PDF

Info

Publication number
CN103153340A
CN103153340A CN2011800476614A CN201180047661A CN103153340A CN 103153340 A CN103153340 A CN 103153340A CN 2011800476614 A CN2011800476614 A CN 2011800476614A CN 201180047661 A CN201180047661 A CN 201180047661A CN 103153340 A CN103153340 A CN 103153340A
Authority
CN
China
Prior art keywords
tumor
disease
mab
subject
purposes according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800476614A
Other languages
English (en)
Chinese (zh)
Inventor
J·西马德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XBIOTECH Inc
Original Assignee
XBIOTECH Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XBIOTECH Inc filed Critical XBIOTECH Inc
Priority to CN201710556357.1A priority Critical patent/CN107281488B/zh
Priority to CN201710452010.2A priority patent/CN107252484A/zh
Publication of CN103153340A publication Critical patent/CN103153340A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2011800476614A 2010-08-23 2011-08-23 对肿瘤疾病的治疗 Pending CN103153340A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710556357.1A CN107281488B (zh) 2010-08-23 2011-08-23 对肿瘤疾病的治疗
CN201710452010.2A CN107252484A (zh) 2010-08-23 2011-08-23 对肿瘤疾病的治疗

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US37609710P 2010-08-23 2010-08-23
US61/376,097 2010-08-23
US40675910P 2010-10-26 2010-10-26
US61/406,759 2010-10-26
US41118310P 2010-11-08 2010-11-08
US61/411,183 2010-11-08
US201161480635P 2011-04-29 2011-04-29
US61/480,635 2011-04-29
PCT/US2011/048747 WO2012027324A2 (en) 2010-08-23 2011-08-23 Treatment for neoplastic diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201710452010.2A Division CN107252484A (zh) 2010-08-23 2011-08-23 对肿瘤疾病的治疗
CN201710556357.1A Division CN107281488B (zh) 2010-08-23 2011-08-23 对肿瘤疾病的治疗

Publications (1)

Publication Number Publication Date
CN103153340A true CN103153340A (zh) 2013-06-12

Family

ID=45594256

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2011800476614A Pending CN103153340A (zh) 2010-08-23 2011-08-23 对肿瘤疾病的治疗
CN201710452010.2A Pending CN107252484A (zh) 2010-08-23 2011-08-23 对肿瘤疾病的治疗
CN201710556357.1A Active CN107281488B (zh) 2010-08-23 2011-08-23 对肿瘤疾病的治疗

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201710452010.2A Pending CN107252484A (zh) 2010-08-23 2011-08-23 对肿瘤疾病的治疗
CN201710556357.1A Active CN107281488B (zh) 2010-08-23 2011-08-23 对肿瘤疾病的治疗

Country Status (17)

Country Link
US (3) US10294296B2 (enExample)
EP (3) EP2608808B1 (enExample)
JP (5) JP6241932B2 (enExample)
KR (7) KR20210128021A (enExample)
CN (3) CN103153340A (enExample)
AU (1) AU2011293554B9 (enExample)
DK (1) DK2608808T3 (enExample)
ES (2) ES2622482T3 (enExample)
IL (2) IL262856B (enExample)
MX (2) MX388939B (enExample)
NZ (1) NZ607472A (enExample)
PH (2) PH12013500316A1 (enExample)
PT (1) PT2608808T (enExample)
RU (2) RU2679119C2 (enExample)
SG (1) SG187853A1 (enExample)
WO (1) WO2012027324A2 (enExample)
ZA (1) ZA201301420B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130098279A (ko) 2010-06-18 2013-09-04 엑스바이오테크, 인크. 관절염 치료
KR20210128021A (ko) 2010-08-23 2021-10-25 얀센 바이오테크 인코포레이티드 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN103906536A (zh) 2011-09-23 2014-07-02 埃克斯生物科技公司 恶病质治疗
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US20170260285A1 (en) * 2014-11-24 2017-09-14 University Of Iowa Research Foundation Methods for treating cancer
AU2018220862A1 (en) 2017-02-16 2019-08-29 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US20060127407A1 (en) * 2004-12-09 2006-06-15 Qiming Chen Anti-integrin immunoconjugates, methods and uses
US20090298096A1 (en) * 2008-05-30 2009-12-03 Xbiotech, Inc. Interleukin-1 alpha ABS and methods of use
WO2010087972A2 (en) * 2009-01-29 2010-08-05 Abbott Laboratories Il-1 binding proteins

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0465513A1 (en) 1989-03-27 1992-01-15 Centocor, Inc. FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES
US5407431A (en) 1989-07-11 1995-04-18 Med-Design Inc. Intravenous catheter insertion device with retractable needle
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
ES2140469T3 (es) 1992-10-14 2000-03-01 Nycomed Imaging As Composiciones y metodos terapeuticos y de diagnostico por obtencion de imagenes.
DE122009000074I1 (de) 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
DE60025832T2 (de) * 1999-08-09 2006-08-31 Emd Lexigen Research Center Corp., Billerica Mehrere zytokin-antikörper komplexen
DE19943790C2 (de) 1999-09-13 2001-11-15 Ericsson Telefon Ab L M Verfahren und Vorrichtung zur Bestimmung eines Synchronisationsfehlers in einem Netzwerkknoten
US6380129B1 (en) 1999-11-02 2002-04-30 Richard J. Kraemer Enhanced materials for treatment of contamination
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20020131954A1 (en) 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
CA2426384A1 (en) 2000-10-19 2003-04-17 Kyowa Hakko Kogyo Co., Ltd. Antibody inhibiting vplf activity
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7348003B2 (en) * 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
KR101033196B1 (ko) 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
EP1483295B1 (en) 2002-03-01 2008-12-10 Immunomedics, Inc. Rs7 antibodies
US7438910B2 (en) 2002-09-06 2008-10-21 Amgen Inc. Therapeutic human anti-IL1-R1 monoclonal antibody
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
NZ544486A (en) 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
KR100493102B1 (ko) 2003-06-30 2005-06-02 삼성전자주식회사 서브 하우징 스토퍼를 구비하는 휴대용 단말기의 힌지 장치
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
ES2346691T3 (es) 2005-08-02 2010-10-19 Xbiotech, Inc Diagnostico, tratamiento y prevencion de trastornos vasculares usando autoanticuerpos il-1alfa.
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
JP5312028B2 (ja) 2005-09-28 2013-10-09 サイトス バイオテクノロジー アーゲー インターロイキン−１コンジュゲート及びその使用
BRPI0709977A2 (pt) 2006-04-14 2011-08-02 Novartis Ag uso de anticorpos de il-1 para o tratamento de distúrbios oftálmicos
US20090191149A1 (en) 2006-05-15 2009-07-30 Xbiotech Inc. IL-1alpha IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
SI2109623T1 (sl) * 2006-05-22 2012-05-31 Xbiotech Inc Zdravljenje raka z anti il protitelesi
US8524865B2 (en) 2006-05-30 2013-09-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
US8324350B2 (en) 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
EP3632444A3 (en) 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
JP5976319B2 (ja) 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
FR2945396A1 (fr) * 2009-05-07 2010-11-12 St Microelectronics Grenoble 2 Procede et dispositif d'analyse de la propagation de transactions dans un reseau multi-protocoles d'un systeme sur puce
UY32949A (es) 2009-10-15 2011-02-28 Abbott Lab Proteínas de unión a il-1
RS57543B1 (sr) 2010-06-03 2018-10-31 Abbvie Biotechnology Ltd Primene i kompozicije za lečenje hidradenitis suppurativa (hs)
KR20130098279A (ko) 2010-06-18 2013-09-04 엑스바이오테크, 인크. 관절염 치료
KR20210128021A (ko) 2010-08-23 2021-10-25 얀센 바이오테크 인코포레이티드 종양성 질병들에 대한 치료
NZ607510A (en) 2010-09-10 2014-10-31 Apexigen Inc Anti-il-1 beta antibodies and methods of use
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
ES2697056T3 (es) 2011-04-01 2019-01-21 Xbiotech Inc Tratamiento para patologías dermatológicas
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。
CN103906536A (zh) 2011-09-23 2014-07-02 埃克斯生物科技公司 恶病质治疗
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
AU2013327498B2 (en) 2012-10-04 2018-06-28 Janssen Biotech, Inc. Treatment of psychiatric conditions
WO2014055544A1 (en) 2012-10-04 2014-04-10 Xbiotech, Inc. Treating vascular disease and complications thereof
EP2975054A4 (en) 2013-03-12 2016-11-23 Zenyaku Kogyo Kk ANTIBODIES TO STAPHYLOKOKEN, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
US20150024031A1 (en) 2013-07-17 2015-01-22 Baxter International Inc. Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent
EP3154584B1 (en) 2014-06-03 2021-08-04 XBiotech Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
AU2018220862A1 (en) 2017-02-16 2019-08-29 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US20060127407A1 (en) * 2004-12-09 2006-06-15 Qiming Chen Anti-integrin immunoconjugates, methods and uses
US20090298096A1 (en) * 2008-05-30 2009-12-03 Xbiotech, Inc. Interleukin-1 alpha ABS and methods of use
WO2010087972A2 (en) * 2009-01-29 2010-08-05 Abbott Laboratories Il-1 binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
APTE RN: "The involvement of IL-1 in tumorigenesis，tumorinvasiveness，metastasis and tumor-host interactions", 《CANCER METASTASIS REV》, vol. 25, no. 3, 31 December 2006 (2006-12-31), pages 387 - 408, XP019447665, DOI: 10.1007/s10555-006-9004-4 *
MELISI D: "Secreted interleukin-1 alpha induces a metastatic phenotype in pancreatic cancer by sustaining a consitutive activation of nuclear factor-kappa B", 《MOL CANCER RES》, vol. 7, no. 5, 31 December 2009 (2009-12-31), pages 624 - 633 *

Also Published As

Publication number Publication date
EP2608808B1 (en) 2017-01-18
RU2017112088A (ru) 2019-01-24
JP2013536236A (ja) 2013-09-19
US11932688B2 (en) 2024-03-19
JP6917681B2 (ja) 2021-08-11
RU2679119C2 (ru) 2019-02-06
IL262856A (en) 2018-12-31
EP3075394A1 (en) 2016-10-05
KR102748255B1 (ko) 2024-12-31
KR101910760B1 (ko) 2018-10-22
KR20160062200A (ko) 2016-06-01
EP2608808A4 (en) 2014-01-15
IL275350B (en) 2021-07-29
MX2013002160A (es) 2013-04-05
JP2021138750A (ja) 2021-09-16
IL262856B (en) 2020-06-30
EP3443985A1 (en) 2019-02-20
AU2011293554B2 (en) 2015-02-26
MX388939B (es) 2025-03-20
KR102314003B1 (ko) 2021-10-19
WO2012027324A3 (en) 2012-05-10
WO2012027324A2 (en) 2012-03-01
KR102104296B1 (ko) 2020-04-27
EP3443985B1 (en) 2020-12-16
EP3075394B1 (en) 2018-11-28
RU2017112088A3 (enExample) 2019-01-24
KR20200010609A (ko) 2020-01-30
ES2856723T3 (es) 2021-09-28
US10294296B2 (en) 2019-05-21
ZA201301420B (en) 2014-04-30
AU2011293554B9 (en) 2015-03-19
PH12013500316A1 (en) 2016-09-02
JP2019194233A (ja) 2019-11-07
PH12016500578A1 (en) 2017-03-06
KR20130108305A (ko) 2013-10-02
JP2025166117A (ja) 2025-11-05
US20120045444A1 (en) 2012-02-23
ES2622482T3 (es) 2017-07-06
KR20210128021A (ko) 2021-10-25
JP6241932B2 (ja) 2017-12-06
IL275350A (en) 2020-07-30
CN107252484A (zh) 2017-10-17
CN107281488A (zh) 2017-10-24
KR20240134401A (ko) 2024-09-09
EP2608808A2 (en) 2013-07-03
PT2608808T (pt) 2017-04-24
JP7316120B2 (ja) 2023-07-27
AU2011293554A1 (en) 2013-03-07
KR20170113687A (ko) 2017-10-12
SG187853A1 (en) 2013-03-28
KR20180116458A (ko) 2018-10-24
US20230382989A1 (en) 2023-11-30
MX342776B (es) 2016-10-12
DK2608808T3 (en) 2017-04-24
RU2013110030A (ru) 2014-09-27
US20190127460A1 (en) 2019-05-02
JP2016175939A (ja) 2016-10-06
NZ607472A (en) 2014-09-26
PH12016500578B1 (en) 2017-03-06
CN107281488B (zh) 2021-02-09

Similar Documents

Publication Publication Date Title
JP7316120B2 (ja) 腫瘍性疾患のための治療
AU2015201228B2 (en) Treatment for neoplastic diseases
AU2015271978B2 (en) Treatment for neoplastic diseases
HK40002544A (en) Treatment for neoplastic diseases
HK40002544B (en) Treatment for neoplastic diseases
HK1229696A1 (en) Treatment for neoplastic diseases
HK1229696B (en) Treatment for neoplastic diseases
HK1182635A (en) Treatment for neoplastic diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1182635

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130612

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1182635

Country of ref document: HK